Q3 Earnings Estimate for Precigen Issued By HC Wainwright

Key Points

• HC Wainwright estimates that Precigen will report Q3 2026 earnings of ($0.01) per share, maintaining a "Buy" rating with a target price of $6.00.
• Precigen's stock recently saw a decrease of 2.4% to $1.87, despite a positive quarterly earnings report that surpassed consensus estimates.
• Institutional investors currently own 33.51% of Precigen's stock, with several hedge funds increasing their positions during the 2nd quarter of 2023.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Stock analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Precigen in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst S. Ramakanth expects that the biotechnology company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a "Buy" rating and a $6.00 price objective on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's Q4 2026 earnings at $0.00 EPS, FY2027 earnings at $0.11 EPS, FY2028 earnings at $0.30 EPS and FY2029 earnings at $0.53 EPS.

PGEN has been the topic of several other reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Precigen in a research report on Thursday, May 15th. JMP Securities reissued a "market outperform" rating and issued a $6.00 price objective on shares of Precigen in a report on Thursday, June 12th. Wall Street Zen raised Precigen from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, JPMorgan Chase & Co. raised shares of Precigen from an "underweight" rating to a "neutral" rating in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Precigen has a consensus rating of "Moderate Buy" and a consensus target price of $6.00.

Precigen Stock Performance

PGEN stock traded up $1.09 during trading on Thursday, hitting $2.94. 173,120,762 shares of the company traded hands, compared to its average volume of 11,864,537. The company has a 50-day moving average of $1.68 and a 200-day moving average of $1.60. The firm has a market capitalization of $876.03 million, a PE ratio of -7.00 and a beta of 1.87. Precigen has a 1 year low of $0.65 and a 1 year high of $3.49.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.67 million. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%.

Hedge Funds Weigh In On Precigen

A number of large investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its stake in Precigen by 3.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock valued at $16,801,000 after purchasing an additional 410,595 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Precigen by 7.7% in the 2nd quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company's stock valued at $5,325,000 after purchasing an additional 269,580 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new position in shares of Precigen during the 1st quarter valued at approximately $4,755,000. Northern Trust Corp increased its stake in shares of Precigen by 11.6% during the fourth quarter. Northern Trust Corp now owns 1,168,689 shares of the biotechnology company's stock worth $1,309,000 after purchasing an additional 121,700 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Precigen by 258.2% in the second quarter. Bank of America Corp DE now owns 832,261 shares of the biotechnology company's stock worth $1,182,000 after acquiring an additional 599,914 shares during the last quarter. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.